- Home
- PCVX vs UTHR Comparison
PCVX vs UTHR Comparison
Compare PCVX & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PCVX
- UTHR
- Stock Information
- Founded
- PCVX 2013
- UTHR 1996
- Country
- PCVX United States
- UTHR United States
- Employees
- PCVX N/A
- UTHR N/A
- Industry
- PCVX Biotechnology: Pharmaceutical Preparations
- UTHR Biotechnology: Pharmaceutical Preparations
- Sector
- PCVX Health Care
- UTHR Health Care
- Exchange
- PCVX Nasdaq
- UTHR Nasdaq
- Market Cap
- PCVX 13.2B
- UTHR 15.5B
- IPO Year
- PCVX 2020
- UTHR 1999
- Fundamental
- Price
- PCVX $86.51
- UTHR $363.25
- Analyst Decision
- PCVX Strong Buy
- UTHR Buy
- Analyst Count
- PCVX 7
- UTHR 14
- Target Price
- PCVX $147.50
- UTHR $370.86
- AVG Volume (30 Days)
- PCVX 1.4M
- UTHR 389.6K
- Earning Date
- PCVX 11-05-2024
- UTHR 10-30-2024
- Dividend Yield
- PCVX N/A
- UTHR N/A
- EPS Growth
- PCVX N/A
- UTHR 25.10
- EPS
- PCVX N/A
- UTHR 22.72
- Revenue
- PCVX N/A
- UTHR $2,756,200,000.00
- Revenue This Year
- PCVX N/A
- UTHR $26.32
- Revenue Next Year
- PCVX N/A
- UTHR $10.37
- P/E Ratio
- PCVX N/A
- UTHR $15.99
- Revenue Growth
- PCVX N/A
- UTHR 25.04
- 52 Week Low
- PCVX $48.24
- UTHR $208.62
- 52 Week High
- PCVX $121.06
- UTHR $417.82
- Technical
- Relative Strength Index (RSI)
- PCVX 23.31
- UTHR 42.87
- Support Level
- PCVX $101.87
- UTHR $396.52
- Resistance Level
- PCVX $107.31
- UTHR $417.82
- Average True Range (ATR)
- PCVX 5.82
- UTHR 12.41
- MACD
- PCVX -2.04
- UTHR -0.95
- Stochastic Oscillator
- PCVX 3.58
- UTHR 26.51
About PCVX Vaxcyte Inc.
Vaxcyte Inc is a vaccine company seeking to improve global health by developing novel vaccines to treat patients suffering from the most common and deadly diseases. Its product comprises. of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-24, VAX-A1, and VAX-PG.
About UTHR United Therapeutics Corporation
United Therapeutics specializes in drug development for pulmonary arterial hypertension, a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. Most of the company's sales are generated within the United States. United Therapeutics also markets a pediatric oncology drug, but its focus largely remains in pulmonary arterial hypertension.